KPV Tripeptide
KPV to suppress chaos in redness-prone skin.
SC injection; IV infusion; oral; topical — 250–500 mcg IV in PRIME/STABILIS formulas; 250 mcg in Melanox Code booster; 500 mcg oral daily for gut protocols
What It Is
KPV is a tripeptide fragment (Lys-Pro-Val) of α-MSH (alpha-melanocyte-stimulating hormone, residues 11–13). It is a potent locally-acting anti-inflammatory agent that blocks NF-κB and mast cell cytokines.
Mechanism
KPV (α-MSH fragment) locally suppresses inflammation in skin and gut. It serves as a "pigment quieting" and redness-dampening signal. It has a strong anti-inflammatory effect — blocking NF-κB and mast cell cytokines — and is particularly useful for rosacea- or melasma-prone patients where it suppresses inflammatory chaos. In IV protocols (PRIME, STABILIS), it reinforces inflammation control without impeding healing.
How Dr. Emer Uses It
Dr. Emer uses KPV in the RE:SKN PRIME IV (250 mcg IV) as a case-directed add-in peptide to enhance inflammation control. Oral or topical KPV is used for gut inflammation concurrent with GLP-1 therapy to protect the GI mucosa. Dr. Emer often summarizes the optional layers succinctly: "KPV to suppress chaos in redness-prone skin; GHK-Cu to lock collagen early; BPC-157 to fortify microvasculature; DSIP to ensure deep recovery sleep." KPV is also given orally (500 mcg daily) starting a week prior for dark skin types, and used in the Melanox Code IV push (250 mcg).
Key Benefits
- ✓Blocks NF-κB and mast cell cytokines to locally suppress inflammation
- ✓Anti-inflammatory in both skin (redness, rosacea) and gut (IBS, colitis)
- ✓Serves as a "pigment quieting" signal to reduce post-inflammatory hyperpigmentation risk
- ✓Reinforces inflammation control without impeding the healing process
- ✓Protects GI mucosa from GLP-1-induced inflammation when given orally
- ✓Particularly effective in darker skin types (Fitzpatrick IV–VI) for redness prevention
Pairs Well With
Used In Programs
Safety & Considerations
Limited human data (derived from melanocyte-stimulating hormone). No major acute risks. Avoid if pregnant. No known issues aside from limited pregnancy data. Well-tolerated in IV and oral forms. Used extensively in RE:SKN protocols without notable adverse events.
Begin Your RECODEX™ Protocol
All peptide therapies are prescribed under direct medical supervision.
Book a Consultation
